117 related articles for article (PubMed ID: 37923172)
1. Yttrium-90 Transarterial Radioembolization of Primary Lung Cancer Metastases to the Liver.
Alexander ES; Petre EN; Zhao K; Sotirchos V; Namakydoust A; Moussa A; Yuan G; Sofocleous CT; Solomon SB; Ziv E
J Vasc Interv Radiol; 2024 Feb; 35(2):214-225.e2. PubMed ID: 37923172
[TBL] [Abstract][Full Text] [Related]
2. Predictors of Survival after Yttrium-90 Radioembolization of Chemotherapy-Refractory Hepatic Metastases from Breast Cancer.
Davisson NA; Bercu ZL; Friend SC; Paplomata E; Ermentrout RM; Newsome J; Majdalany BS; Kokabi N
J Vasc Interv Radiol; 2020 Jun; 31(6):925-933. PubMed ID: 32307310
[TBL] [Abstract][Full Text] [Related]
3. Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study.
Gangi A; Shah J; Hatfield N; Smith J; Sweeney J; Choi J; El-Haddad G; Biebel B; Parikh N; Arslan B; Hoffe SE; Frakes JM; Springett GM; Anaya DA; Malafa M; Chen DT; Chen Y; Kim RD; Shridhar R; Kis B
J Vasc Interv Radiol; 2018 Aug; 29(8):1101-1108. PubMed ID: 30042074
[TBL] [Abstract][Full Text] [Related]
4. Relationship of radiation dose to efficacy of radioembolization of liver metastasis from breast cancer.
Ridouani F; Soliman MM; England RW; Hsu M; Moskowitz CS; Doustaly R; Sofocleous CT; Boas FE; Yarmohammadi H; Deipolyi AR
Eur J Radiol; 2021 Mar; 136():109539. PubMed ID: 33476965
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry.
Wong TY; Zhang KS; Gandhi RT; Collins ZS; O'Hara R; Wang EA; Vaheesan K; Matsuoka L; Sze DY; Kennedy AS; Brown DB
BMC Cancer; 2022 Mar; 22(1):224. PubMed ID: 35232410
[TBL] [Abstract][Full Text] [Related]
6.
Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N
Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086
[TBL] [Abstract][Full Text] [Related]
7. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study.
Kolligs F; Arnold D; Golfieri R; Pech M; Peynircioglu B; Pfammatter T; Ronot M; Sangro B; Schaefer N; Maleux G; Munneke G; Pereira H; Zeka B; de Jong N; Helmberger T;
JHEP Rep; 2023 Feb; 5(2):100633. PubMed ID: 36593888
[TBL] [Abstract][Full Text] [Related]
8. Role of Radioembolization in the Management of Liver-Dominant Metastatic Renal Cell Carcinoma: A Single-Center, Retrospective Study.
Bibok A; Mhaskar R; Jain R; Zhang J; Frakes J; Hoffe S; El-Haddad G; Parikh N; Ahmed A; Fishman MN; Choi J; Kis B
Cardiovasc Intervent Radiol; 2021 Nov; 44(11):1755-1762. PubMed ID: 34312688
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Toxicity after Transarterial Radioembolization with Yttrium-90 Using Resin Microspheres for Neuroendocrine Tumor Liver Metastases.
Tomozawa Y; Jahangiri Y; Pathak P; Kolbeck KJ; Schenning RC; Kaufman JA; Farsad K
J Vasc Interv Radiol; 2018 Jun; 29(6):858-865. PubMed ID: 29724520
[TBL] [Abstract][Full Text] [Related]
10. The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study.
Abdallah MA; Wongjarupong N; Hassan MA; Taha W; Abdalla A; Bampoh S; Onyirioha K; Nelson M; Glubranson LA; Wiseman GA; Fleming CJ; Andrews JC; Mahipal A; Roberts LR
Expert Rev Gastroenterol Hepatol; 2020 Jul; 14(7):619-629. PubMed ID: 32490691
[TBL] [Abstract][Full Text] [Related]
11. Yttrium-90 Radioembolization of Advanced, Unresectable Breast Cancer Liver Metastases-A Single-Center Experience.
Pieper CC; Meyer C; Wilhelm KE; Block W; Nadal J; Ahmadzadehfar H; Willinek WA; Schild HH
J Vasc Interv Radiol; 2016 Sep; 27(9):1305-1315. PubMed ID: 27461588
[TBL] [Abstract][Full Text] [Related]
12. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with
Hermann AL; Dieudonné A; Ronot M; Sanchez M; Pereira H; Chatellier G; Garin E; Castera L; Lebtahi R; Vilgrain V;
Radiology; 2020 Sep; 296(3):673-684. PubMed ID: 32602828
[TBL] [Abstract][Full Text] [Related]
13. Toxicity and Survival of Hepatocellular Carcinoma Patients with Hepatitis B Infection Treated with Yttrium-90 Radioembolization: An Updated 15-Year Study.
Gao R; Gabr A; Mouli S; Riaz A; Kulik L; Lewandowski RJ; Salem R
J Vasc Interv Radiol; 2020 Mar; 31(3):401-408.e1. PubMed ID: 31983593
[TBL] [Abstract][Full Text] [Related]
14. Survival and Toxicities after Yttrium-90 Transarterial Radioembolization of Cholangiocarcinoma in the RESiN Registry.
Robinson TJ; Du L; Matsuoka L; Sze DY; Kennedy AS; Gandhi RT; Kouri BE; Collins ZS; Kokabi N; Grilli CJ; Wang EA; Lee JS; Brown DB
J Vasc Interv Radiol; 2023 Apr; 34(4):694-701.e3. PubMed ID: 36509236
[TBL] [Abstract][Full Text] [Related]
15. Lung Shunt Fraction prior to Yttrium-90 Radioembolization Predicts Survival in Patients with Neuroendocrine Liver Metastases: Single-Center Prospective Analysis.
Ludwig JM; Ambinder EM; Ghodadra A; Xing M; Prajapati HJ; Kim HS
Cardiovasc Intervent Radiol; 2016 Jul; 39(7):1007-14. PubMed ID: 26964779
[TBL] [Abstract][Full Text] [Related]
16. Computed tomographic perfusion imaging for the prediction of response and survival to transarterial radioembolization of liver metastases.
Morsbach F; Pfammatter T; Reiner CS; Fischer MA; Sah BR; Winklhofer S; Klotz E; Frauenfelder T; Knuth A; Seifert B; Schaefer N; Alkadhi H
Invest Radiol; 2013 Nov; 48(11):787-94. PubMed ID: 23748229
[TBL] [Abstract][Full Text] [Related]
17. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis.
Egger ME; Armstrong E; Martin RC; Scoggins CR; Philips P; Shah M; Konda B; Dillhoff M; Pawlik TM; Cloyd JM
J Am Coll Surg; 2020 Apr; 230(4):363-370. PubMed ID: 32032719
[TBL] [Abstract][Full Text] [Related]
18. A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis.
Gonsalves CF; Eschelman DJ; Adamo RD; Anne PR; Orloff MM; Terai M; Hage AN; Yi M; Chervoneva I; Sato T
Radiology; 2019 Oct; 293(1):223-231. PubMed ID: 31453767
[TBL] [Abstract][Full Text] [Related]
19. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib.
Teyateeti A; Mahvash A; Long J; Abdelsalam M; Avritscher R; Kaseb A; Odisio B; Ravizzini G; Surasi D; Teyateeti A; Macapinlac H; Kappadath SC
World J Gastroenterol; 2021 Dec; 27(47):8166-8181. PubMed ID: 35068861
[TBL] [Abstract][Full Text] [Related]
20. Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial.
Mulcahy MF; Mahvash A; Pracht M; Montazeri AH; Bandula S; Martin RCG; Herrmann K; Brown E; Zuckerman D; Wilson G; Kim TY; Weaver A; Ross P; Harris WP; Graham J; Mills J; Yubero Esteban A; Johnson MS; Sofocleous CT; Padia SA; Lewandowski RJ; Garin E; Sinclair P; Salem R;
J Clin Oncol; 2021 Dec; 39(35):3897-3907. PubMed ID: 34541864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
